# Royalty Pharma plc (RPRX) FY2026 Q2 Balance Sheet

- Company: Royalty Pharma plc (RPRX)
- Period: As of 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001802768-26-000015
- Page: https://plicit.ai/financials/rprx/fy2026-q2-balance-sheet
- Chart image: https://plicit.ai/charts/rprx-fy2026-q2-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 19,819,771,000 US dollars
- **Current assets**: 1,764,570,000 US dollars
- **Non-current assets**: 18,055,201,000 US dollars
- **Liabilities**: 10,034,057,000 US dollars
- **Current liabilities**: 630,928,000 US dollars
- **Non-current liabilities**: 9,403,129,000 US dollars
- **Equity**: 9,785,714,000 US dollars
- **Noncontrolling interest**: 2,952,975,000 US dollars. Included in consolidated equity; this amount is not added again.
- **Financial royalty assets**: 889,454,000 US dollars
- **Cash and cash equivalents**: 811,986,000 US dollars
- **Other royalty income receivable**: 31,474,000 US dollars
- **Available for sale debt securities**: 25,000,000 US dollars
- **Other current assets**: 6,656,000 US dollars
- **Financial royalty assets, net**: 16,192,717,000 US dollars
- **Goodwill**: 923,535,000 US dollars
- **Available for sale debt securities**: 372,100,000 US dollars
- **Equity method investments**: 261,973,000 US dollars
- **Equity securities**: 241,918,000 US dollars
- **Other assets**: 62,958,000 US dollars
- **Current portion of long-term debt**: 380,000,000 US dollars
- **Interest payable**: 107,766,000 US dollars
- **Distributions payable to non-controlling interests**: 91,280,000 US dollars
- **Accounts payable and accrued liabilities**: 35,566,000 US dollars
- **Other current liabilities**: 16,316,000 US dollars
- **Long-term debt**: 8,581,892,000 US dollars
- **Accrued compensation liabilities**: 713,219,000 US dollars
- **Other liabilities**: 108,018,000 US dollars
- **Additional paid-in capital**: 4,376,266,000 US dollars
- **Retained earnings**: 2,459,089,000 US dollars
- **Common stock - Class R Redeemable Shares**: 63,000 US dollars
- **Common stock - Class A Ordinary Shares**: 45,000 US dollars
- **Deferred shares, $0.000001 par value; issued and outstanding: 2026–430,189 and 2025–411,475**: 0 US dollars
- **Common stock - Class B Ordinary Shares**: 0 US dollars
- **Non-controlling interests**: 2,952,975,000 US dollars
- **Treasury interests**: negative 2,724,000 US dollars
- **Gross equity (calculated)**: 9,788,438,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.